REG - Hemogenyx Pharma Plc - Second Patient Treated with HG-CT-1 CAR-T Therapy

Hemogenyx PharmaceuticalsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250502:nRSB1507Ha&default-theme=true

RNS Number : 1507H  Hemogenyx Pharmaceuticals PLC  02 May 2025

 

2 May 2025

 

Hemogenyx Pharmaceuticals plc

 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Second Patient Treated with HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the
second patient has been successfully treated as part of the Company's ongoing
Phase I clinical trial of HG-CT-1, its proprietary CAR-T cell therapy for the
treatment of relapsed or refractory acute myeloid leukemia ("R/R AML") in
adults.

This milestone follows the successful first-in-human treatment with HG-CT-1,
which demonstrated a favorable initial safety profile with no adverse effects
observed, and the subsequent recruitment of the second patient. Together,
these milestones mark steady progress in the clinical development of HG-CT-1
and reinforce the Company's commitment to advancing treatment options for
patients with limited therapeutic alternatives.

The Phase I trial is a dose-escalation study designed to assess the safety
profile of HG-CT-1 and to collect data on key secondary endpoints, including
anti-leukemic activity, overall survival, progression-free survival, and
duration of response.

The Company believes that continued clinical execution will not only advance a
potentially transformative treatment for adult patients with limited
therapeutic options but also generate long-term value for shareholders by
establishing HG-CT-1 as a platform-defining asset in the field of hematologic
malignancies. While the current trial is focused on adult patients, successful
initial outcomes would pave the way for a pediatric trial - an area of
significant unmet medical need in AML, where few effective treatment options
exist for children.

Further updates on the clinical trial will be provided in due course.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"The treatment of a second patient with HG-CT-1 marks another critical step in
the development of our CAR-T therapy for relapsed or refractory AML. The
ability to move forward with dosing reflects the capabilities of our
scientific and manufacturing teams and further validates our platform. We
remain deeply focused on executing the clinical program with rigor and care,
and on our mission to bring potentially life-saving treatments to patients in
need."

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

 

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPSFESPSEFA